We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

By LabMedica International staff writers
Posted on 04 Nov 2024
Print article
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve. While survival is possible for children with SVHDs, their quality of life is significantly affected due to having only one functional ventricle. This serious congenital heart defect requires immediate treatment after birth. As the number of fetal therapies increases, the importance of early diagnosis becomes even more pronounced. Early detection of congenital heart diseases during pregnancy would not only provide physicians with additional time to plan treatment but also reduce the financial burden on families. It would enable them to consider earlier therapeutic options that could enhance survival rates and improve outcomes for newborns facing life-threatening heart conditions. Currently, the standard method for diagnosing congenital heart disease prenatally occurs at the five-month mark of pregnancy through ultrasound, at which point the disease is usually advanced enough to be visually identified. This method relies on imaging technology and equipment, leading to increased healthcare costs and heightened risks of healthcare inequity.

Researchers at Nationwide Children's Hospital (Columbus, OH, USA) have now discovered a potential biomarker that could detect the presence of SVHDs in a fetus through a maternal blood test. This test analyzes elevated levels of cell-free microRNAs (miRNAs) in the blood of mothers carrying a fetus with single ventricle heart disease. According to a research letter published in Circulation Research, these cell-free miRNAs could eventually serve as noninvasive biomarkers for earlier prenatal detection of single ventricle heart diseases.

In their study, the researchers utilized deep sequencing to identify elevated cell-free miRNAs in the maternal blood of pregnant participants carrying a fetus diagnosed with SVHD. They also employed induced pluripotent stem cells (iPSCs) to examine the functions of these miRNAs in the proliferation of human cardiomyocytes. The findings suggest that these cell-free miRNAs in maternal blood hold promise as noninvasive biomarkers for the prenatal detection of fetal SVHDs, pending additional animal studies and clinical validation.

“This technology is in an early phase; preclinical studies and additional clinical validation is needed, but we are encouraged by what this could mean for the evolution of detecting and managing single ventricle heart diseases in children,” said Mingtao Zhao, DVM, PhD, senior author of the study and associate professor in the Center for Cardiovascular Research at Nationwide Children’s. “This is a step toward further improved outcomes for newborns with congenital heart diseases.
 

New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
Repeater Pipette
CAPPR10 Repeater Pipette
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.